CA-ARGONAUT-MANUF-SVCS
Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, announced today the completion of a $45 million financing to support its new drug product fill / finish expansion. This expansion in Carlsbad, CA, underway since early 2023, includes a new dedicated facility with a state-of-the-art isolator-based filling line that more than quadruples Argonaut’s existing drug product fill / finish capacity and augments existing vial filling capabilities with the ability to pre-fill syringes and cartridges for clinical and commercial supply. Argonaut expects to have fully validated the facility and all equipment in 2025.
The financing was led by NewVale Capital, a growth equity fund focused on innovative pharmaceutical and life science services businesses, with participation from existing majority investor Telegraph Hill Partners, and other current investors.
Wayne Woodard, founder and CEO of Argonaut, commented: “Argonaut is uniquely positioned to address the manufacturing challenges that biopharma innovators face related to sterile fill / finish of complex and high-value drug products. We remain laser focused on leveraging our experienced team’s commitment to flexibility and client satisfaction while prioritizing quality and compliance. The recent commitment from NewVale Capital and the continued support of Telegraph Hill Partners paves a straight path to capacity expansion and fulfillment of our mission to become the world’s best Drug Product Manufacturing solutions provider for our clients.”
“We are thrilled to partner with Telegraph Hill to support the experienced team at Argonaut, building upon their strong foundation,” said Todd Holmes, Managing Partner of NewVale Capital. “For years, small- and medium-sized biopharma companies have struggled to find reliable, high-quality fill / finish capabilities from providers that prioritize their molecules. With this capital infusion, we can further enable Argonaut’s mission that no innovator, regardless of size, should be waitlisted behind larger pharma or be forced to compromise on quality when trying to bring critical therapies to patients.”
Argonaut’s FDA-registered facilities are compliant with 21 CFR parts 210, 211, and 820 and offer highly flexible and scalable solutions for a broad range of biopharmaceuticals including monoclonal antibodies, proteins, peptides, oligonucleotides, and small molecules. Additionally, Argonaut maintains an ISO 13485:2016 certification to produce drug-device combination products. Argonaut’s quality systems have been successfully audited by many biopharma customers and global regulatory agencies including the FDA and PMDA.
“The recent consolidation in the aseptic fill / finish market has highlighted the need for additional capacity to ensure patients have uninterrupted access to critical life-saving and life-extending therapies,” stated Chris Duffy, SVP/GM of Biopharma Services at Argonaut. “Our deep expertise in fill / finish, coupled with our planned expansion will help address this need for our clients and we remain ready to take on new projects.”
RBC Capital Markets LLC served as exclusive placement agent to Argonaut.
About Argonaut Manufacturing Services
Argonaut Manufacturing Services is an FDA-registered cGMP contract development and manufacturing organization (CDMO) dedicated to providing custom manufacturing and supply chain solutions for biopharmaceutical and diagnostic companies. Aseptic drug fill / finish capabilities feature state-of-the-art automated equipment for high-yield filling of sterile injectable drugs including biologics, peptides, small molecules, and vaccines. Diagnostic manufacturing capabilities include proprietary lyophilization technology and a spectrum of kitting capabilities. Projects are supported with full analytical quality control services including warehousing and global shipping logistics. Serving innovators in the biopharma, life science, and molecular diagnostics industries, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs. For more information, visit: www.argonautms.com.
About Telegraph Hill Partners
Founded in 2001, Telegraph Hill Partners invests in life science, medical device, and healthcare technology companies. For more information, visit: www.telegraphhillpartners.com.
About NewVale Capital
Founded in 2022, NewVale Capital is a growth equity firm that focuses on supporting the next generation of life science services companies. The firm invests in proven, revenue-generating services businesses across the life science ecosystem that are helping to bring medicines to patients. For more information, visit: www.newvalecapital.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305644445/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom